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Abstract
Osteoarthritis (OA) is caused by both biochemical and mechanical factors. While the mechanisms that underlie the disease are not completely 
understood, investigators have characterized a number of catabolic and protective factors that have a role in the disease process. Nitric oxide 
(NO) and its redox derivatives appear to have a number of different functions in both normal and pathophysiological joint conditions. Until 
recently, NO was considered a catabolic factor that was responsible for perpetuating the OA disease process by mediating the expression of 
proinﬂammatory cytokines, inhibiting the synthesis of collagen and proteoglycans and inducing apoptosis. However, recent studies suggest 
that NO and its redox derivatives may also have protective effects on cartilage. This review will summarize the literature on the effects of NO 
on cartilage and chondrocytes as well as discuss some evidence that suggests potential protective effects of NO and/or its derivatives on 
other cell types. More research is needed to elucidate the role of NO and its derivatives on both normal and osteoarthritis cartilage.
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Introduction
Osteoarthritis (OA) is the most common arthritis condition 
and is a major cause of impaired mobility and disability world-
wide.1 Although literature on the incidence and prevalence 
of OA is limited, worldwide estimates indicate that 9.6% of 
men and 18% of women 60 years have symptomatic OA.1
Estimates of hand OA in adults 26 years was 6.8% and this 
number increased to 26.2% in women and 13.4% in men 
71 years.2 Since both obesity3 and aging4 are associated 
with increasing rates of OA, the prevalence of OA is likely to 
continue to rise. Pharmacological management of OA using 
non-steroidal anti-inﬂammatory drugs (NSAIDs) and analge-
sics is palliative and results in some control of pain, improve-
ment in function and quality of life while limiting drug toxicity. 
However, there are ongoing safety concerns with NSAIDs 
that drive the search for efﬁcient pain relief combined with 
a stronger safety proﬁle. An emerging new class of drugs 
called COX-inhibiting nitric oxide donors (CINODs) have the 
potential to improve cardiovascular safety by lowering the 
potential for increasing hypertension and potentially sparing 
damage to the gastrointestinal tract.5 Because nitric oxide 
(NO) donors improve vascular endothelial function with the 
hypothesized beneﬁt of less damage to the gastrointestinal 
mucosa, CINODs may be safe and effective new drugs for 
the treatment of pain and inﬂammation associated with OA. 
This paper reviews the biology of NO in OA and discusses 
the potential role of NO-donating compounds in the treat-
ment of OA. 
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NO and osteoarthritis
Nitric oxide (NO) is synthesized by conversion of L-argi-
nine to NOH-arginine and ultimately to L-citrulline plus NO 
(Figure 1). The reaction is catalyzed by 1 of 3 isoforms of 
nitric oxide synthase (NOS) enzyme which oxidizes one of 
the guanidinyl nitrogens of arginine to anhydroxy arginine 
which is further oxidized to citrulline and NO.6 A simple view 
of NO signaling is that after its synthesis, NO diffuses out 
of the cell and activates soluble cyclic guanylate cyclase 
(sGC) to produce activated cGMP from GTP. cGMP then 
speciﬁcally binds to target proteins which include protein 
kinases, phosphodiesterases, and cyclic nuclear ion chan-
nels to elicit a number of biological effects. 
Osteoarthritis is a degenerative disease process which 
is caused by a number of events including both mechani-
cal and biochemical factors. Osteoarthritic chondrocytes 
produce a number of inﬂammatory mediators including 
IL-1, TNF-Į, prostaglandins and NO (Figure 2).7,8 NO is 
expressed in human osteoarthritis cartilage as illustrated 
by immunostaining with anti-nitrotyrosine antibodies.9 In 
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Fig. 1. The synthesis and fate of NO in cells.
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addition, the inducible nitric oxide synthase (iNOS) enzyme 
is also upregulated in OA chondrocytes, resulting in an 
excess of NO and perpetuating the release of inﬂamma-
tory cytokines and other catabolic processes.10 NO inhib-
its both proteoglycan and collagen synthesis,11 activates 
metalloproteinases, mediates chondrocyte apoptosis and 
promotes chondrocyte inﬂammatory responses. All of these 
activities contribute to the catabolic consequences of NO 
in cartilage. However, there is recent evidence demonstrat-
ing that peroxynitrite, a redox derivative of NO, may have 
an opposing activity in cytokine-stimulated chondrocytes,12
suggesting the role of NO in OA may be more complex than 
originally believed. 
Nitric oxide synthases in osteoarthritis
Chondrocytes from osteoarthritic cartilage overexpress 
iNOS preferentially in the superﬁcial zone, suggesting that 
these tissues are actively producing NO.10,13 Furthermore, 
iNOS is induced by both mechanical and biochemical fac-
tors, including inﬂammatory mediators such as IL-1ȕ and 
TNF-Į. NF-țB, a transcription factor whose activity is regu-
lated by NO and its redox derivatives, is also required for 
transcription of the iNOS gene.14 The importance of iNOS 
expression and the subsequent increase of NO in the patho-
genesis of OA is reinforced by in vivo experiments demon-
strating that speciﬁc inhibition of iNOS results in decreased 
production of catabolic factors such as IL-1ȕ, matrix metal-
loproteinases (MMPs) and peroxynitrite.15 Further, biome-
chanical forces result in an increase in the expression of 
iNOS protein, but not of protein levels of either constitutive 
NOS enzyme.16 Experiments in iNOS knockout mice have 
shown them to be resistant to experimental OA,17 demon-
strating that NO generated from the upregulation of iNOS 
plays a role in the catabolic events of OA. These experi-
ments suggest that iNOS inhibition is a potential therapeutic 
target for disease-modifying therapy. However, given recent 
studies suggesting that redox derivatives of NO may have 
an anti-inﬂammatory role in chondrocytes, it is clear that 
NO and its derivatives do not have a straightforward role in 
the progression of OA and it is possible that NO and per-
oxynitrite could have opposing function in the development 
of inﬂammation and arthritis.
Nitric oxide and proteoglycan and collagen 
synthesis
Experiments performed by Taskiran and colleagues illus-
trated that NO inhibited the synthesis of both proteogly-
cans and collagen in rabbit cartilage cultures.11 In human 
alginate cultures of articular chondrocytes, endogenously 
produced NO inhibited the synthesis of proteoglycans from 
both the superﬁcial and deep cartilage zone.18 However, in 
the presence of the NOS inhibitor NG-monomethyl-L-argi-
nine (L-NMA), the suppression of proteogylcan synthesis 
was completely reversed in the deep chondrocytes but only 
partially reversed in the superﬁcial zones, suggesting that 
NO may be a protective agent in response to proteogylcan 
catabolism.18
Adding to the complexity of the known catabolic effects 
of NO in the pathogenesis of OA, NO has also been shown 
to promote cartilage deposition in other cell types and tis-
sues. For example, in human tendon cells stimulated with 
low doses of exogenous NO delivered as SNAP, total pro-
tein synthesis and procollagen synthesis both increased.19
An increase in protein and procollagen synthesis was seen 
when an adenovirus containing the iNOS gene was trans-
fected into the tendon cells. Likewise, rats that underwent 
trauma/hemorrhagic trauma were given an intraperitoneal 
injection of L-arginine before wounding had increased pro-
collagen I and II mRNA expression compared to animals 
that received a saline injection.20 However, it is important 
to note that plasma NO levels were not signiﬁcantly differ-
ent between the control and L-arginine animals, making it 
Cartilage
breakdown
products
PA/Plasmin
Latent MMPs
Cartilage
Mechanical
forces
TIMPs
PA inhibitor
MMP-13
BMP-2
Apoptosis
Osteoblast
Osteoclast
Bone
Osteophyte
Type x
     collagen
IL-8
IL-1
IL-1
NO
PGE2
TNF-
?TNF-
?
–
NO
Active
MMPs
Aggrecanases
Synovium
Fig. 2. Inﬂammatory mediators produced by cartilage and synovium (reprinted from reference 8 with permission). BMP = bone morphogenic 
protein, IL = interkeukin, MMP = matrix metalloproteinase, NO = nitric oxide, PA = plasminogen, PGE = prostaglandin E, TGF = transforming 
growth factor, TIMP = tissue inhibitor of metalloproteinase, TNF = tumor necrosis factor. 
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impossible to determine whether the increase in procolla-
gen mRNA was caused by an increase in NO signaling or 
another mechanism. It is clear that NO signaling has oppos-
ing effects under different conditions and more research is 
clearly needed to elucidate the mechanism for these vary-
ing responses to increases in NO. 
Nitric oxide and inflammatory mediators
A number of inﬂammatory mediators have been shown to 
play a pathogenic role in the development of OA. In ex vivo 
conditions, NO is spontaneously released in human osteo-
arthritis-affected cartilage but not normal cartilage. NO 
mediates the effects of a number of proinﬂammatory cyto-
kines, including IL-1ȕ and TNF-Į. In vivo experiments using 
a canine osteoarthritis model demonstrated that stimulation 
of chondrocytes by NO is responsible in part for the subse-
quent upregulation of IL-18 synthesis as well as the syn-
thesis of interleukin-1-converting enzyme (ICE), a caspase 
required for maturation of both IL-1ȕ and IL-18.21 When the 
animals were fed N-iminoethyl-L-lysine (L-NIL), a speciﬁc 
iNOS inhibitor, levels of ICE and IL-18 were signiﬁcantly 
decreased in cartilage from the femoral condyles and tibial 
plateaus. NO stimulation also downregulated the level of 
protease inhibitor 9 (PI-9), a natural inhibitor of ICE, result-
ing in increased IL-1ȕ and IL-18 activity which may help 
contribute to the catabolic effects on OA tissue. Finally, in 
vitro experiments demonstrated that there was a signiﬁcant 
inhibition of ICE. Inhibitors of p38, MED-1/2 and COX-2, 
but not the iNOS inhibitor L-NIL, inhibited the levels of ICE 
protein, demonstrating that NO is not required for ICE syn-
thesis21 which will perpetuate the inﬂammatory response by 
maturing proinﬂammatory cytokines. 
Nitric oxide and metalloproteinases
NO also mediates the upregulation of matrix metallopro-
teinases (MMPs). Incubation of rabbit chondrocytes with 
IL-1 resulted in an increase in the mRNA transcripts for 
MMP-1, 2, 3 and 9. When the cells were incubated with 
a combination of IL-1 and the NO production inhibitor Nc-
monomethyl-L-arginine (NMA), the expression of MMP-9 
mRNA decreased, suggesting that NO is required for the 
expression of MMP-9.22 More recent in vitro studies using 
murine macrophages demonstrated that NO and reactive 
nitrogen species (RNS) can regulate the activity of MMP-
9 in a biphasic and ﬂux-dependent manner.23 Low levels 
of exogenous NO enhanced MMP-9 activity and sup-
pressed endogenous MMP/tissue inhibitor of metallopro-
teinase (TIMP)-1 activity in a cGMP-dependent process. 
When exposed to a NO-donor leading to higher steady-
state concentrations of NO (500 nM), secreted MMP-9 was 
activated. However, at NO levels exceeding 1 mM, MMP-9 
was inactivated and these reactions are distinct from the 
disruption of the MMP/TIMP-1 balance.23 These results 
demonstrate that matrix remodeling is controlled by NO at 
a number of different stages, suggesting again that NO may 
have multiple roles in the regulation of MMP activity in OA-
affected cartilage. Further experiments demonstrated that 
reactive oxygen species (ROS), likely hydrogen peroxide, 
act as second messengers for ﬁbronectin fragment-stimu-
lated MMP production in human articular chondrocytes.24
The authors demonstrated that pretreatment of cells with 
antioxidants, but not NOS inhibitors, resulted in inhibition 
of MMP production, demonstrating that redox derivatives of 
NO are responsible for upregulation of MMPs and subse-
quent matrix degradation,24 thereby adding to the catabolic 
effects of NO on cartilage.
Nitric oxide and apoptosis
NO has been reported to be a key inducer of chondro-
cyte apoptosis, a central pathogenic feature of OA. It has 
been suggested that either endogenous or exogenous NO 
can induce apoptosis in chondrocytes via a mitochondria-
dependent mechanism.25,26 For example, when human 
chondrocytes are exposed to either exogenous NO via incu-
bation with sodium nitroprusside (SNP) or endogenous NO 
via incubation with lipopolysccharide (LPS) and interferon 
(IFN)-Ȗ, NO, ROS and cytochrome C levels all increase, 
as does caspace-3 activation and DNA fragmentation, all 
hallmarks of apoptosis. Treatment with the NOS inhibitor 
L-NMA decreased NO levels as well as the other markers of 
apoptosis.25,26 However, there have also been recent reports 
suggesting that peroxynitrite may be primarily responsible 
for chondrocyte apoptosis through a caspase-independent 
mechanism. Whiteman et al.27 used human articular chon-
drocytes to study the mechanism by which peroxynitrite 
leads to cell death. Although the authors determined that 
increased peroxynitrite led to a rise in intracellular calcium 
and mitochondrial dysfunction, they did not see evidence of 
caspace-3 activation, a marker of apoptosis. Rather, they 
found evidence suggesting that calcium-dependent prote-
ases called calpains led to chondrocyte cell death, showing 
the ﬁrst evidence that mitochondrial dysfunction can result 
in caspase-independent apoptosis.
Nitric oxide and NF-țB activation
NO and its derivatives can regulate cytokine-induced NF-țB
activation in cartilage. In resting cells, NF-țB is inactive and 
retained in the cytoplasm by IțB. In response to proinﬂam-
matory signals, IțB is phosphyorylated; it dissociates from 
NF-țB and allows the translocation of NF-țB to the nucleus. 
Once in the nucleus, NF-țB helps mediate transcription of 
proinﬂammatory genes including IL-1ȕ, TNF-Į, iNOS and 
other catabolic factors including MMPs. NO is required for 
the sustained activation of NF-țB. In cells incubated with IL-
1ȕ alone, NF-țB translocates to the nucleus. The addition 
of exogenous NO, delivered as S-nitrocysteine ethyl ester 
(SNCEE), decreases the number of cells with NF-țB in the 
nucleus. However, incubation with the free radical derivative 
peroxynitrite increased the number of cells with NF-țB in the 
nucleus.12 These results suggest that when chondrocytes 
are exposed to inﬂammatory signals, the effects of induced 
NO are to sustain the activation of NF-țB, perpetuating the 
inﬂammatory response. However, this does not preclude 
the possibility that under less inﬂammatory conditions, the 
intracellular redox potential could favor S-nitrosothiol pro-
duction by chondrocytes, resulting in inhibitory effects NO 
production on NF-țB activation.
There is also evidence that NO can help downregulate 
NF-țB activity. For example, Reynaert, et al.28 used lung epi-
thelial and Jurkat T cells to demonstrate that S-nitrosylation
of a speciﬁc cysteine residue in IKKȕ can inhibit its activa-
tion, thereby preventing NF-țB from transclocating to the 
nucleus. The authors suggest that the identiﬁcation of IKKȕ
as a substrate for S -nitrosylation could lead to new strate-
gies to utilize NO-donors as anti-inﬂammatory agents.
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Regulation of iNOS 
NO has also been shown to down-regulate iNOS gene 
expression in cultured hepatocytes. In these experiments, 
Chang, et al.29 demonstrated that isolated rat hepato-
cytes incubated with cytokines had increased expression 
of iNOS mRNA and protein as well as increased levels of 
NO. However, when the cells were pretreated with the NO-
donors S-nitroso-N-acetyl-D,L, penicillamine (SNAP) and 
V-PYRRO/NO, iNOS mRNA and protein levels were signiﬁ-
cantly reduced. In addition, when cells were pretreated with 
oxidized SNAP, NO2– or NO3–, there was no reduction of 
iNOS mRNA or protein, demonstrating that NO is required 
for increased expression of iNOS. The authors also dem-
onstrated a similar effect in a macrophage cell line. When 
the cells were exposed to LPS and INF-Ȗ, there was an 
increase in both NO and iNOS mRNA. However, when 
the cells were treated with the NOS inhibitor NMA (which 
decreases the production of NO), there was increased 
expression of iNOS, IL-1ȕ, IL-6, and TNF-Į genes. These 
results show that in at least two cell types, NO can mediate 
a decrease in iNOS gene expression, which helps regulate 
the effects of NO ﬂuctuations. 
Nitric oxide and prostaglandins
Like NO, levels of prostaglandin-E2 (PGE2) are also 
increased in osteoarthritis and are spontaneously released 
in ex vivo conditions in osteoarthritis-affected cartilage.13,30
PGE2 is a predominant product of cyclooygenase-2 (COX-2)
and can exert both catabolic and anabolic effects in carti-
lage. PGE2 can also reverse the proteoglycan degradation 
induced by IL-1ȕ stimulation in both human and bovine 
cartilage explants. Experiments in healthy human cartilage 
demonstrated that PGE2 alone has no effect on proteogly-
can turnover in healthy cartilage. However, when cultured 
in the presence of IL-1ȕ and TNF-Į, proteoglycan turnover 
is increased and addition of PGE2 enhanced this turnover. 
When PGE2 production is inhibited by selective COX-2 inhi-
bition, the adverse effects of IL-1ȕ and TNF-Į are reversed.31
The experiments also demonstrated that there was a nega-
tive correlation between NO production and proteoglycan 
synthesis and a positive correlation between NO production 
and proteoglycan release. The authors do point out, how-
ever, that there are a number of reports demonstrating that 
inhibition of PGE2 production has no effect on NO produc-
tion.32,33 They conclude that numerous pathways, including 
NO production, are likely to help PGE2 modulate proteogyl-
can synthesis, again linking NO production to the catabolic 
effects of OA.
Nitric oxide and reactive oxygen species
Finally, NO can combine with superoxide anions (O2–) to 
generate peroxynitrite, which has also been implicated in 
both proinﬂammatory and proapoptotic effects on carti-
lage. Bovine chondrocytes incubated with IL-1ȕ show an 
increase in both intracellular peroxynitrite and superoxide 
anion generation.34 Peroxynitrite exposure enhanced cyto-
kine-induced NF-țB activation whereas incubation with an 
exogenous NO source inhibited cytokine-induced NF-țB
activation.12 Peroxynitrite also has proapoptotic effects on 
cartilage.27 It can induce mitochondrial dysfunction in cells 
in a calcium-dependent process that triggers caspase-inde-
pendent apoptosis, again illustrating that NO derivatives 
play an important role in the destructive events of OA.
Conclusion
The mechanisms underlying the catabolic and possible pro-
tective effects of NO and its redox derivatives on cartilage 
are not completely understood. There is however, clear evi-
dence in these in vitro studies that there are anti-inﬂamma-
tory effects as well as the well-described catabolic effects 
(Figure 3). Only further study will allow an understanding of 
this complex cascade of events. There are other papers later 
in this supplement to describe other possible beneﬁts of NO 
donation justifying the development of such therapies. 
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Fig. 3. The yin-yang effects of NO on cartilage and synovial tissues. 
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